These days a $5 note won't get you very much. You may just be able to scrape a tall skinny latte from Starbucks or perhaps a value pizza from Domino's Pizza Enterprises Ltd. (ASX: DMP).
Or alternatively you could put that money to use and buy a single share in one of the exciting companies listed below. All have share prices of under $5.
a2 Milk Company Ltd (Australia) (ASX: A2M)
This fast-growing dairy company continues to go from strength to strength despite the changes to regulations in China which led to Bellamy's Australia Ltd (ASX: BAL) recent problems. In November, a2 Milk revealed that sales up to the end of October were up 96% on the prior corresponding period. Pleasingly management recently responded to investor concerns (around Bellamy's) and confirmed that business remains strong, noting significant year-on-year growth in its infant formula segment. Although no longer a bargain buy, I think a2 Milk still represents a great buy and hold investment.
BWX Ltd (ASX: BWX)
BWX is the company behind the popular Sukin skincare range. In the last three months its share price has tumbled almost 20%, making it a potential bargain buy now in my opinion. Its shares are changing hands at 21x estimated FY 2017's earnings according to CommSec, which I believe is a great price as earnings are forecast to grow by approximately 35% per annum for the next couple of years. A big driver of this growth will be its international sales which will receive a boost this year after Sukin's launch in the Boots pharmacy chain in the United Kingdom.
Mayne Pharma Group Ltd (ASX: MYX)
Last year was a rollercoaster of a year for shareholders of this growing pharmaceutical company. At one stage its share price had gained over 55%, but ultimately it finished the year flat as price-fixing allegations weighed on its share price. I found the sell-off surprising as management has consistently reiterated that any fines imposed would not be material. With such a lucrative pipeline of generic drugs due to be released in the year ahead and its shares priced at 15x estimated forward earnings, I think Mayne Pharma would be a great investment.
